Pharmacotherapy for primary CNS lymphoma: Progress beyond methotrexate?

Jerome J. Graber, Antonio Omuro

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Studies conducted in the 1990s have established that high-dose methotrexate-based chemotherapy added to whole-brain radiotherapy improves survival in primary CNS lymphoma (PCNSL). However, radiotherapy-related delayed neurotoxicity has emerged as a serious complication of chemo-radiotherapy, particularly in the elderly. Unfortunately, omitting radiotherapy results in decreased progression-free survival, and therefore establishing more effective chemotherapy regimens is necessary in order to improve the number of long-term remissions. Recent studies have suggested that a combination of drugs is superior to single-agent methotrexate, but the optimal chemotherapy combination and the role of alternative consolidation treatments such as reduced-dose radiotherapy and high-dose chemotherapy with stem cell rescue remain to be defined. In this article, we review the multiple chemotherapy options reported in newly diagnosed and in progressiverefractory PCNSL, including recently reported and ongoing clinical trials, as well as future perspectives.

Original languageEnglish (US)
Pages (from-to)447-457
Number of pages11
JournalCNS Drugs
Volume25
Issue number6
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Methotrexate
Lymphoma
Radiotherapy
Drug Therapy
Drug Combinations
Combination Drug Therapy
Disease-Free Survival
Stem Cells
Clinical Trials
Brain
Therapeutics

Keywords

  • Antineoplastics
  • CNS-cancer
  • Lymphoma
  • Methotrexate
  • Radiotherapy
  • Stem-cell-transplant

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Clinical Neurology

Cite this

Pharmacotherapy for primary CNS lymphoma : Progress beyond methotrexate? / Graber, Jerome J.; Omuro, Antonio.

In: CNS Drugs, Vol. 25, No. 6, 2011, p. 447-457.

Research output: Contribution to journalArticle

Graber, Jerome J. ; Omuro, Antonio. / Pharmacotherapy for primary CNS lymphoma : Progress beyond methotrexate?. In: CNS Drugs. 2011 ; Vol. 25, No. 6. pp. 447-457.
@article{3574d63013274f079922362ee497b7af,
title = "Pharmacotherapy for primary CNS lymphoma: Progress beyond methotrexate?",
abstract = "Studies conducted in the 1990s have established that high-dose methotrexate-based chemotherapy added to whole-brain radiotherapy improves survival in primary CNS lymphoma (PCNSL). However, radiotherapy-related delayed neurotoxicity has emerged as a serious complication of chemo-radiotherapy, particularly in the elderly. Unfortunately, omitting radiotherapy results in decreased progression-free survival, and therefore establishing more effective chemotherapy regimens is necessary in order to improve the number of long-term remissions. Recent studies have suggested that a combination of drugs is superior to single-agent methotrexate, but the optimal chemotherapy combination and the role of alternative consolidation treatments such as reduced-dose radiotherapy and high-dose chemotherapy with stem cell rescue remain to be defined. In this article, we review the multiple chemotherapy options reported in newly diagnosed and in progressiverefractory PCNSL, including recently reported and ongoing clinical trials, as well as future perspectives.",
keywords = "Antineoplastics, CNS-cancer, Lymphoma, Methotrexate, Radiotherapy, Stem-cell-transplant",
author = "Graber, {Jerome J.} and Antonio Omuro",
year = "2011",
doi = "10.2165/11589030-000000000-00000",
language = "English (US)",
volume = "25",
pages = "447--457",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Pharmacotherapy for primary CNS lymphoma

T2 - Progress beyond methotrexate?

AU - Graber, Jerome J.

AU - Omuro, Antonio

PY - 2011

Y1 - 2011

N2 - Studies conducted in the 1990s have established that high-dose methotrexate-based chemotherapy added to whole-brain radiotherapy improves survival in primary CNS lymphoma (PCNSL). However, radiotherapy-related delayed neurotoxicity has emerged as a serious complication of chemo-radiotherapy, particularly in the elderly. Unfortunately, omitting radiotherapy results in decreased progression-free survival, and therefore establishing more effective chemotherapy regimens is necessary in order to improve the number of long-term remissions. Recent studies have suggested that a combination of drugs is superior to single-agent methotrexate, but the optimal chemotherapy combination and the role of alternative consolidation treatments such as reduced-dose radiotherapy and high-dose chemotherapy with stem cell rescue remain to be defined. In this article, we review the multiple chemotherapy options reported in newly diagnosed and in progressiverefractory PCNSL, including recently reported and ongoing clinical trials, as well as future perspectives.

AB - Studies conducted in the 1990s have established that high-dose methotrexate-based chemotherapy added to whole-brain radiotherapy improves survival in primary CNS lymphoma (PCNSL). However, radiotherapy-related delayed neurotoxicity has emerged as a serious complication of chemo-radiotherapy, particularly in the elderly. Unfortunately, omitting radiotherapy results in decreased progression-free survival, and therefore establishing more effective chemotherapy regimens is necessary in order to improve the number of long-term remissions. Recent studies have suggested that a combination of drugs is superior to single-agent methotrexate, but the optimal chemotherapy combination and the role of alternative consolidation treatments such as reduced-dose radiotherapy and high-dose chemotherapy with stem cell rescue remain to be defined. In this article, we review the multiple chemotherapy options reported in newly diagnosed and in progressiverefractory PCNSL, including recently reported and ongoing clinical trials, as well as future perspectives.

KW - Antineoplastics

KW - CNS-cancer

KW - Lymphoma

KW - Methotrexate

KW - Radiotherapy

KW - Stem-cell-transplant

UR - http://www.scopus.com/inward/record.url?scp=79958158726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958158726&partnerID=8YFLogxK

U2 - 10.2165/11589030-000000000-00000

DO - 10.2165/11589030-000000000-00000

M3 - Article

C2 - 21649446

AN - SCOPUS:79958158726

VL - 25

SP - 447

EP - 457

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 6

ER -